Surgery for Cerebral Stroke
Online ISSN : 1880-4683
Print ISSN : 0914-5508
ISSN-L : 0914-5508
Original Articles
Initial Treatment Experience with Clazosentan for Cerebral Vasospasm after Subarachnoid Hemorrhage
Toru WATANABEYoshio ARAKIKenji UDAJunpei IENAGANobuyasu KATOYuichiro ISOZAWAYosuke SAKAITetsuya TSUKADATakayuki ISHIKAWAYusuke SAKAMOTOShinsuke MURAOKATetsuya NAGATANIYukio SEKIRyuta SAITO
Author information
JOURNAL FREE ACCESS

2024 Volume 52 Issue 4 Pages 258-264

Details
Abstract

Clazosentan is used to suppress the onset of cerebral vasospasm, delayed cerebral ischemia (DCI), and new cerebral infarctions after subarachnoid hemorrhage. Here we retrospectively examine our initial experience using this drug in our department. Evaluation items included patient background factors, clinical characteristics, spasms on imaging, DCI/new cerebral infarction, complications associated with fluid retention, and other complications. Thirty-two patients were included; among them, clazosentan was administered to 25. In the clazosentan group, 10 patients (31%) exhibited spasms on imaging, one (4%) experienced DCI, and four (16%) had a new cerebral infarction. Complications associated with fluid retention occurred in 13 patients (52%). Although differences were observed in the phase III study in patient background factors, clinical characteristics, and concomitant medications, clazosentan effectively prevented DCI and new cerebral infarctions. Additional cases should be examined to establish an ideal body fluid management protocol.

Content from these authors
© 2024 by The Japanese Society on Surgery for Cerebral Stroke
Previous article Next article
feedback
Top